Kraig Biocraft Laboratories Announces the Launch of Advanced Gene-Splicing Program and New Transgenics
Kraig Biocraft Laboratories (OTCQB: KBLB) has announced the successful implementation of a next-generation molecular biology and gene-splicing platform. This advancement represents a significant upgrade in the company's genetic engineering capabilities for spider silk production.
The company has already validated the technology by creating a new transgenic silkworm, which is currently undergoing evaluation testing and commercial application assessment. Kraig Labs is experimenting with two such platforms and plans to adopt one for all ongoing and future commercial silkworm development programs.
This technological upgrade is expected to enable more precise, efficient, and versatile DNA manipulation, accelerating the R&D pipeline for advanced materials and enhancing material performance. The company is actively transitioning all silkworm biotechnology programs to these next-generation platforms to improve efficiency, consistency, and performance in spider silk production.
Kraig Biocraft Laboratories (OTCQB: KBLB) ha annunciato l'implementazione con successo di una piattaforma di biologia molecolare e splicing genico di nuova generazione. Questo progresso rappresenta un miglioramento significativo nelle capacità di ingegneria genetica dell'azienda per la produzione di seta di ragno.
L'azienda ha già convalidato la tecnologia creando un nuovo baco da seta transgenico, attualmente in fase di valutazione e analisi per applicazioni commerciali. Kraig Labs sta sperimentando due piattaforme di questo tipo e prevede di adottarne una per tutti i programmi commerciali di sviluppo del baco da seta in corso e futuri.
Questo aggiornamento tecnologico dovrebbe consentire una manipolazione del DNA più precisa, efficiente e versatile, accelerando il processo di ricerca e sviluppo di materiali avanzati e migliorando le prestazioni dei materiali. L'azienda sta attivamente trasferendo tutti i programmi biotecnologici sui bachi da seta a queste piattaforme di nuova generazione per aumentare efficienza, coerenza e performance nella produzione di seta di ragno.
Kraig Biocraft Laboratories (OTCQB: KBLB) ha anunciado la exitosa implementación de una plataforma de biología molecular y splicing génico de próxima generación. Este avance representa una mejora significativa en las capacidades de ingeniería genética de la compañía para la producción de seda de araña.
La empresa ya ha validado la tecnología creando un nuevo gusano de seda transgénico, que actualmente está en fase de pruebas de evaluación y análisis para su aplicación comercial. Kraig Labs está experimentando con dos plataformas de este tipo y planea adoptar una para todos los programas comerciales de desarrollo de gusanos de seda en curso y futuros.
Se espera que esta actualización tecnológica permita una manipulación del ADN más precisa, eficiente y versátil, acelerando la línea de I+D para materiales avanzados y mejorando el rendimiento de los materiales. La compañía está en proceso de transición de todos los programas biotecnológicos de gusanos de seda a estas plataformas de próxima generación para mejorar la eficiencia, consistencia y desempeño en la producción de seda de araña.
Kraig Biocraft Laboratories (OTCQB: KBLB)는 차세대 분자생물학 및 유전자 스플라이싱 플랫폼의 성공적인 도입을 발표했습니다. 이 발전은 거미줄 생산을 위한 회사의 유전공학 역량을 크게 향상시키는 의미 있는 업그레이드입니다.
회사는 이미 새로운 형질전환 누에를 만들어 이 기술을 검증했으며, 현재 평가 테스트와 상업적 적용 가능성 검토 중에 있습니다. Kraig Labs는 두 가지 플랫폼을 실험 중이며, 진행 중인 모든 상업용 누에 개발 프로그램에 하나를 채택할 계획입니다.
이번 기술 업그레이드는 더 정밀하고 효율적이며 다용도의 DNA 조작을 가능하게 하여 첨단 소재 연구개발 속도를 가속화하고 소재 성능을 향상시킬 것으로 기대됩니다. 회사는 거미줄 생산의 효율성, 일관성 및 성능 향상을 위해 모든 누에 생명공학 프로그램을 이 차세대 플랫폼으로 적극 전환하고 있습니다.
Kraig Biocraft Laboratories (OTCQB : KBLB) a annoncé la mise en œuvre réussie d'une plateforme de biologie moléculaire et de recombinaison génétique de nouvelle génération. Cette avancée représente une amélioration significative des capacités d'ingénierie génétique de l'entreprise pour la production de soie d'araignée.
L'entreprise a déjà validé cette technologie en créant un nouveau ver à soie transgénique, actuellement en phase d'évaluation et d'examen pour une application commerciale. Kraig Labs expérimente deux plateformes de ce type et prévoit d'en adopter une pour tous les programmes commerciaux de développement de vers à soie en cours et futurs.
Cette mise à niveau technologique devrait permettre une manipulation de l'ADN plus précise, efficace et polyvalente, accélérant ainsi la recherche et développement de matériaux avancés et améliorant les performances des matériaux. L'entreprise est en train de transférer activement tous ses programmes biotechnologiques liés aux vers à soie vers ces plateformes de nouvelle génération afin d'améliorer l'efficacité, la cohérence et les performances dans la production de soie d'araignée.
Kraig Biocraft Laboratories (OTCQB: KBLB) hat die erfolgreiche Implementierung einer molekularbiologischen und Gen-Spleiß-Plattform der nächsten Generation bekanntgegeben. Dieser Fortschritt stellt eine bedeutende Verbesserung der genetischen Ingenieurfähigkeiten des Unternehmens zur Herstellung von Spinnenseide dar.
Das Unternehmen hat die Technologie bereits validiert, indem es einen neuen transgenen Seidenspinner geschaffen hat, der derzeit in der Evaluierungs- und kommerziellen Anwendungsprüfung ist. Kraig Labs experimentiert mit zwei solchen Plattformen und plant, eine für alle laufenden und zukünftigen kommerziellen Seidenspinner-Entwicklungsprogramme zu übernehmen.
Dieses technologische Upgrade soll eine präzisere, effizientere und vielseitigere DNA-Manipulation ermöglichen, die F&E-Pipeline für fortschrittliche Materialien beschleunigen und die Materialleistung verbessern. Das Unternehmen stellt aktiv alle Biotechnologieprogramme für Seidenspinner auf diese Plattformen der nächsten Generation um, um Effizienz, Konsistenz und Leistung bei der Spinnenseidenproduktion zu steigern.
- Successfully implemented next-generation gene-splicing platform
- Already created and validated new transgenic silkworm
- Technology enables faster R&D development and improved DNA manipulation
- Platform expected to increase production efficiency and material performance
- Final platform selection still pending between two options
- New transgenic silkworm still in evaluation phase without proven commercial viability
Company Adopting Advanced Gene Editing Platform Across All Commercial Silkworm Development Programs
ANN ARBOR, Mich., April 15, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company" or "Kraig Labs"), a world leader in spider silk technology1, today announced the successful rollout of a next-generation molecular biology and gene-splicing platform. This powerful new system represents a major leap forward in the Company's ability to create and refine genetically engineered spider silk and other advanced materials. The Company has already validated the technology with a newly created transgenic.
Leveraging cutting-edge advancements in gene editing, this platform enables more precise, efficient, and versatile manipulation of DNA. As a result, Kraig Labs has rapidly developed a new transgenic silkworm, which is now undergoing evaluation testing and commercial application assessment.
This breakthrough empowers Kraig Labs to significantly accelerate its R&D pipeline for advanced materials and enhance material performance.
"Our adaption of this technology represents a transformative advancement for Kraig Labs and our entire molecular biology program," said Company Founder and CEO, Kim Thompson. "With this platform in place, we are dramatically expanding the speed, scope, and sophistication of our genetic engineering capabilities. The successful creation of new transgenics using this system confirms its effectiveness. We are experimenting with two such platforms and will likely adopt one of them for all of our ongoing and future commercial silkworm development."
Kraig Labs is now actively transitioning all of its silkworm biotechnology programs to these next-generation platforms, which is expected to drive increased efficiency, consistency, and performance in spider silk production.
This development marks another milestone in the Company’s mission to lead the commercialization of high-performance spider silk materials for a broad range of end markets, including technical textiles, defense, performance apparel, and medical textiles.
For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.
For details about other recent Kraig Labs advancements, please watch the Company's investor conference at www.kraiglabs.com/videos or on the Company's YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270.
1For a description of our historical leadership in this technology please follow this link https://www.kraiglabs.com/world-leader/
To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.
The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.
Ben Hansel, Hansel Capital, LLC
(720) 288-8495
ir@KraigLabs.com
FAQ
What is the significance of KBLB's new gene-splicing platform announcement?
How has KBLB validated their new gene-editing technology?
What are the expected benefits of KBLB's new gene-splicing platform?
How many gene-editing platforms is KBLB currently testing?
